Physician profile
Jay G Levine
NPI 1366473845
$1,451.35
in general payments reported to CMS, 2019-2025
23 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $20.19 · 2021: $90.64 · 2022: $164 · 2023: $383 · 2024: $470 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $241.68 | 2024-2025 | Cygnus Dual, Via Matrix, Puraply Am |
| Amgen INC. | $179.71 | 2021-2024 | Prolia, Evenity, Repatha |
| Corcept Therapeutics | $169.80 | 2020-2023 | Korlym |
| Smith+Nephew, INC. | $150.86 | 2024 | Pico, Renasys Touch, Renasys Go V2 Home |
| Abbott Laboratories | $113.86 | 2022-2024 | Freestyle Libre |
| Crossroads Extremity Systems, LLC | $93.34 | 2019 | |
| Mannkind Corporation | $92.37 | 2023 | Afrezza |
| Novo Nordisk INC | $44.87 | 2024-2025 | Sogroya |
| Verity Pharmaceuticals INC. | $39.19 | 2024-2025 | Tlando |
| Ibsa Pharma INC. | $36.65 | 2023-2024 | Tirosint, Licart, Licart |
| Recordati_rare_diseases_inc. | $34.75 | 2022-2023 | Signifor Lar, Isturisa |
| Antares Pharma, INC. | $32.67 | 2024 | Xyosted |
| Merck Sharp & Dohme LLC | $26.15 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $22.98 | 2023 | |
| Lilly USA, LLC | $21.91 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $21.25 | 2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $20.07 | 2024 | |
| Exact Sciences Corporation | $19.92 | 2023 | Cologuard Collection Kit |
| Eusa Pharma (US) LLC | $19.90 | 2022 | |
| Neurocrine Biosciences, INC. | $18.38 | 2025 | |
| Alvogen INC | $17.85 | 2024 | Teriparatide |
| Paratek Pharmaceuticals, INC. | $17.46 | 2024 | Nuzyra |
| Averitas Pharma INC. | $15.73 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.